/

Società

Me

Non verificato

Merck

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

38 comunicati stampa

Guarda tutti i comunicati

08/06/2026

Annunci Economici

Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector

Fonte

Emittente

1.00

0

21/05/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Industria

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

Fonte

Emittente

1.00

0

07/05/2026

Annunci Economici

Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies

Fonte

Emittente

1.00

0

30/04/2026

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Fonte

Emittente

1.00

0

21/04/2026

Annunci Economici

Merck Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography

Fonte

Emittente

1.00

0

01/04/2026

Annunci Economici

Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio

Fonte

Emittente

1.00

0

18/03/2026

Annunci Economici

Merck Marks 10 Years of SPARK™ Mobilizing Employee Volunteers to Help Inspire the Next Generation in STEM

Fonte

Emittente

1.00

0

12/01/2026

Eventi

Industria

Salute

Farmaceutica

Medicina - Varie

Oncologia

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Fonte

Emittente

1.00

0

12/01/2026

Eventi

Industria

Salute

Farmaceutica

Medicina - Varie

Oncologia

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Fonte

Emittente

1.00

0

22/12/2025

Oncologia

Auto/Automotive

Salute

Sanità

Farmaceutica

Industria

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0